A Multicenter, Randomized, Naturalistic, Open-Label Study Between Aripiprazole and Standard of Care in the Management of Community-Treated Schizophrenic Patients (Schizophrenia Trial of Aripiprazole - STAR)

Trial Profile

A Multicenter, Randomized, Naturalistic, Open-Label Study Between Aripiprazole and Standard of Care in the Management of Community-Treated Schizophrenic Patients (Schizophrenia Trial of Aripiprazole - STAR)

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2013

At a glance

  • Drugs Aripiprazole (Primary) ; Olanzapine; Quetiapine; Risperidone
  • Indications Schizophrenia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms STAR
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 14 Apr 2011 Actual end date (1 Aug 2005) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top